

MELANOMA BRIDGE
November 30th - December 2nd, 2023

SCIENTIFIC RATIONAL

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in different approaches to target and harness the immune response.

Approval of new immune - and target - therapies has further improved outcomes for patients with advanced melanoma.

The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

This year latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the session dedicated to system biology on immunotherapy, immunogenicity and gene expression profiling and focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.

Then, the “Great Debate” sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view.



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.

PRELIMINARY SCIENTIFIC PROGRAM

**Speakers to be invited*
***Not included on CME accredited program*

November 30th, 2023

Melanoma Bridge Opening Session**

Chairpersons: Paolo A. Ascierto, Francesco Marincola*

- | | | |
|---------|------|--|
| 6.00 PM | 6.15 | Advances in melanoma screening**, <i>Laura K. Ferris</i> |
| 6:15 PM | 6:35 | Artificial intelligence in melanoma research: the pros and cons**, <i>Iman Osman</i> |
| 6:35 PM | 6:55 | Lecture title to be defined**, <i>Samir N. Khleif</i> |
| 6:55 PM | 7:20 | Patient Advocacy, <i>Samantha Guild, Claudia Piazza Cidonio</i> |

December 1st, 2023

- | | | |
|------|------|---|
| 9:20 | 9:30 | Introduction and objectives, <i>Paolo A. Ascierto</i> |
|------|------|---|

Session 1 – MELANOMA IS MODEL FOR CANCER IMMUNOTHERAPY

Chairpersons: Giuseppe Masucci, Magdalena Thurin*

- | | | |
|-------|-------|---|
| 9:30 | 9:45 | Title to be defined, <i>Bernard A. Fox*</i> |
| 9:45 | 9:50 | Q&A |
| 9:50 | 10:05 | Challenges in ICI era, <i>Marc S. Ernstoff*</i> |
| 10:05 | 10:10 | Q&A |
| 10:10 | 10:25 | Neoadjuvant in Melanoma, <i>Christian Blank</i> |
| 10:25 | 10:30 | Q&A |
| 10:30 | 10:45 | Is Seeing Believing with Immunotherapy? <i>Michael A. Postow</i> |
| 10:45 | 10:50 | Q&A |
| 10:50 | 11:05 | New interesting target from recent phase 1 studies, <i>Omid Hamid</i> |
| 11:05 | 11:10 | Q&A |
| 11:10 | 11:25 | IO toxicities and management, <i>Ryan Sullivan</i> |
| 11:25 | 11:30 | Q&A |



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.

11:30 12:20 SYMPOSIUM

12:20 12:50 LECTURE

12:50 1:40 Lunch**

Session 2 – MELANOMA TUMOR BIOLOGY

Chairperson: Mario Mandalà

1:40 1:55 T-cell sensitivity to “self” antigens, *Michelle Krogsgaard**

1:55 2:10 Melanoma immune biology, *Amanda Lund**

2:10 2:25 Melanoma biology in the context of clinical and experimental resistance, *Roger Lo*

2:25 2:40 Targeting Ras in melanoma, *Poulikos Poulikakos**

2:40 3:10 Discussion

3:10 4:00 SYMPOSIUM - Paolo A. Ascierto, Reinhard Dummer*

GREAT DEBATE Session

Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov, Alessandro Testori

4:00 4:30 Brain metastases treatment: Car-T cell therapy VS Car-NK cell therapy
*Hussein Tawbi VS Katy Rezvani**

4:30 4:40 Discussion

4:40 5:10 Do we need a new AJCC classification? Yes or No
Claus Garbe VS Jeffrey E. Gershenwald**

5:10 5:20 Discussion

5:20 5:50 Clinical drugs development phase 1-2-3 VS novel trials design
*Igor Puzanov VS Mustafa Khasraw**

5:50 6:00 Discussion

6:00 6:30 Radiomics VS molecular imaging
Caroline Robert VS Elisabeth G. E. de Vries**

6:30 6:40 Discussion



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.

December 2nd, 2023

Session 3 – EMERGENT STRATEGIES

Chairpersons: Nicola Normanno*, Giuseppe Palmieri

- 9:30 9:45 Title to be defined, *Janice Mehnert*
- 9:45 9:50 Q&A
- 9:50 10:05 mRNA Vaccine in High-Risk Melanoma, *Jeffrey Weber*
- 10:05 10:10 Q&A
- 10:10 10:25 New therapeutic target, *Thomas Gajewski**
- 10:25 10:30 Q&A
- 10:30 10:45 Engineered T cells, *Olivier Michielin*
- 10:45 10:50 Q&A
- 10:50 11:05 Uveal Melanoma, *Richard Carvajal**
- 11:05 11:10 Q&A
- 11:10 11:25 Novel technologies and systems innovation on modern melanoma care,
*Thach-Giao Truong**
- 11:25 11:30 Q&A
- 11:30 11:45 Major shift in melanoma management are emerging: high risk for relapse identification in
primary melanomas and neoadjuvant immunotherapy developments, *Alexander Eggermont*
- 11:45 11:50 Q&A
- 11:50 12:05 Non-immune based therapy in the BRAFv600 WT melanoma, *Jeffrey Sosman*
- 12:05 12:10 Q&A
- 12:10 12:25 Electrochemotherapy, *Corrado Caracò*
- 12:25 12:30 Q&A
- 12:30 1:00 LECTURE**
- 1:00 2:00 Lunch****
- 2:00 2:50 SYMPOSIUM**



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.

GREAT DEBATE Session

Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov, Alessandro Testori

- 2:50 3:20 PD-L1 in melanoma: is it useful? Yes or No
Michael B. Atkins VS Alexander M.M. Eggermont*
- 3:20 3:30 Discussion
- 3:30 4:00 What is better treatment for PD-1 refractory melanoma?
Tumor infiltrating lymphocyte therapy vs. nivolumab + ipilimumab
*Allison Betof Warner VS Ari Vanderwalde**
- 4:00 4:10 Discussion
- 4:10 4:40 What is the best initial treatment for unresectable mucosal melanoma?
Nivolumab + ipilimumab VS PD-1 + VEGF inhibition
Alexander Shoushtari VS Jun Guo**
- 4:40 4:50 Discussion
- 4:50 5:05 Putting it all together – Practical Considerations for Monday Clinic, *Sanjiv S. Agarwala**
- 5:05 5:10 Conclusions, *Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov*



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.

PRESIDENCY

Paolo A. Ascierto, Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS “Fondazione G. Pascale”, Naples, Italy

Corrado Caracò, Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS “Fondazione G. Pascale”, Naples, Italy

Iman Osman, Rudolf L. Baer MD Professor of Dermatology, Professor, Departments of Medicine (Oncology) and Urology, Director, Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, NYU Grossman School of Medicine, New York, NY, US

Igor Puzanov, Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

SCIENTIFIC BOARD

Sanjiv S. Agarwala, Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

Paolo A. Ascierto, Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS “Fondazione G. Pascale”, Naples, Italy

Carlo Bifulco, Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory; Director, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Elizabeth M. Burton, Director, Research Planning & Development, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

Lisa H. Butterfield, Adjunct Professor, Microbiology and Immunology, University of California San Francisco; Vice President, PICI Research Center/ PICI Research & Development, San Francisco, CA, US

Corrado Caracò, Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS “Fondazione G. Pascale”, Naples, Italy

Mary Dean, Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

Sandra Demaria, Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology, Weill Cornell Medical College, New York, NY, US

Reinhard Dummer, Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

Alexander M.M. Eggermont, Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical & Translational Immunotherapy, Utrecht University, Utrecht, Netherland



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.

Leisha A. Emens, Professor of Medicine, Director of Translational Immunotherapy for the Women's Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, UPMC Hillman Cancer Center/Magee Women's Hospital, Pittsburgh, PA, US

Bernard A. Fox, Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Jerome Galon, Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

Claus Garbe, Professor of Dermatology; President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

Jeffrey E. Gershenwald, Professor of Cancer Biology, Departments of Surgical Oncology and Cancer Biology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Houston, TX, US

Omid Hamid, Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

Giuseppe Masucci, Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

Olivier Michielin, Full Professor, Chair of Precision Oncology Center, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland

Iman Osman, Rudolf L. Baer MD Professor of Dermatology, Professor, Departments of Medicine (Oncology) and Urology, Director, Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, NYU Grossman School of Medicine, New York, NY, US

Giuseppe Palmieri, Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

Michael A. Postow, Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

Igor Puzanov, Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Magdalena Thurin, Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

Tara Withington, Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US



3P Solution S.r.l. a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH.